156 related articles for article (PubMed ID: 12106845)
1. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug.
Aronow WS; Ahn C
Am J Cardiol; 2002 Jul; 90(2):147-9. PubMed ID: 12106845
[No Abstract] [Full Text] [Related]
2. Incidence of new atherothrombotic brain infarction in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol >or=125 mg/dl treated with statins versus no lipid-lowering drug.
Aronow WS; Ahn C; Gutstein H
J Gerontol A Biol Sci Med Sci; 2002 May; 57(5):M333-5. PubMed ID: 11983729
[TBL] [Abstract][Full Text] [Related]
3. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug.
Aronow WS; Ahn C
Am J Cardiol; 2002 Jan; 89(1):67-9. PubMed ID: 11779527
[No Abstract] [Full Text] [Related]
4. Ciprofibrate and lipid profile.
Chandler HA; Batchelor AJ
Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
[No Abstract] [Full Text] [Related]
5. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
[TBL] [Abstract][Full Text] [Related]
6. Trends in lipids and lipoproteins in US adults, 1988-2010.
Carroll MD; Kit BK; Lacher DA; Shero ST; Mussolino ME
JAMA; 2012 Oct; 308(15):1545-54. PubMed ID: 23073951
[TBL] [Abstract][Full Text] [Related]
7. Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug.
Aronow WS; Ahn C
Am J Cardiol; 2002 Oct; 90(7):789-91. PubMed ID: 12356403
[No Abstract] [Full Text] [Related]
8. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the lipid profile of elderly women in Curitiba - Parana.
Krause MP; Hallage T; Miculis CP; Gama MP; Silva SG
Arq Bras Cardiol; 2008 May; 90(5):299-304. PubMed ID: 18516398
[TBL] [Abstract][Full Text] [Related]
10. [Micronized fenofibrate, decreased triglyceride levels, total cholesterol and LDL fractions in serum].
Zaborska B; Kłoś J; Sikora-Frac M; Cybulska B; Ceremuzyński L
Pol Arch Med Wewn; 2000 Jul; 104(1):371-5. PubMed ID: 11303327
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Papademetriou V; Piller LB; Ford CE; Gordon D; Hartney TJ; Geraci TS; Reisin E; Sumner BM; Wong ND; Nwachuku C; Narayan P; Haywood J; Habib G;
J Clin Hypertens (Greenwich); 2003; 5(6):377-84. PubMed ID: 14688492
[TBL] [Abstract][Full Text] [Related]
12. Using lipid-lowering agents effectively. When diet is not enough.
Scott D; Kurenitz M
Postgrad Med; 1990 Jun; 87(8):171-6, 179-81, 186. PubMed ID: 2189126
[TBL] [Abstract][Full Text] [Related]
13. [Hypolipidemic agents and their indication].
Teramoto T
Nihon Rinsho; 2001 Mar; 59 Suppl 3():559-65. PubMed ID: 11347132
[No Abstract] [Full Text] [Related]
14. An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics.
Vincenzi B; Borba CP; Gray DA; Copeland PM; Wang X; Fan X; Aragam GG; Henderson DC
Ann Clin Psychiatry; 2013 May; 25(2):141-8. PubMed ID: 23638445
[TBL] [Abstract][Full Text] [Related]
15. Lipid-lowering therapy and cholesterol levels following acute myocardial infarction: a German study of 5361 patients.
Bergmann A; Schulze J; Hübner D; Weizel A; Julius U; Kreuzer J
Eur J Epidemiol; 2003; 18(5):407-11. PubMed ID: 12889686
[TBL] [Abstract][Full Text] [Related]
16. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
17. Only a fraction of patients with ischaemic diseases or diabetes are treated to recommended target values for plasma lipids.
Siggaard-Andersen N; Freiberg JJ; Nordestgaard BG
Dan Med J; 2012 Jul; 59(7):A4470. PubMed ID: 22759845
[TBL] [Abstract][Full Text] [Related]
18. Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients.
Egede R; Jensen LO; Hansen HS; Antonsen L; Hansen KN; Junker A; Thayssen P
Int J Cardiol; 2012 Jul; 158(3):376-9. PubMed ID: 21349594
[TBL] [Abstract][Full Text] [Related]
19. Reduction of new coronary events and new atherothrombotic brain infarction in older persons with diabetes mellitus, prior myocardial infarction, and serum low-density lipoprotein cholesterol >/=125 mg/dl treated with statins.
Aronow WS; Ahn C; Gutstein H
J Gerontol A Biol Sci Med Sci; 2002 Nov; 57(11):M747-50. PubMed ID: 12403804
[TBL] [Abstract][Full Text] [Related]
20. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
